- Report
- March 2025
- 200 Pages
Global
From €2266EUR$2,490USD£1,943GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- October 2024
- 237 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- October 2024
- 244 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- October 2023
- 157 Pages
Global
From €4232EUR$4,650USD£3,628GBP
- Report
- July 2018
- 30 Pages
China
From €2002EUR$2,200USD£1,716GBP
- Report
- February 2023
- 220 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Drug Pipelines
- January 2019
- 163 Pages
Global
From €20022EUR$22,000USD£17,165GBP
- Report
- July 2018
- 27 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Drug Pipelines
- January 2024
- 30 Pages
Global
From €455EUR$500USD£390GBP
- Report
- October 2024
- 90 Pages
Global
From €3500EUR$4,120USD£3,106GBP

Plavix (clopidogrel) is a medication used to prevent blood clots in people with certain cardiovascular conditions. It is a thienopyridine class antiplatelet drug, which works by inhibiting the binding of adenosine diphosphate (ADP) to its platelet receptor and blocking the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. This reduces the ability of platelets to form clots, thus reducing the risk of stroke, heart attack, and other cardiovascular events. Plavix is used to treat acute coronary syndrome, peripheral artery disease, and other conditions. It is also used to reduce the risk of stroke and other cardiovascular events in people with a history of stroke or transient ischemic attack.
The Plavix market is a subset of the larger cardiovascular drugs market, which includes medications used to treat and prevent cardiovascular diseases. This market includes drugs used to treat hypertension, dyslipidemia, and other cardiovascular conditions. It also includes drugs used to prevent and treat heart failure, arrhythmias, and other cardiovascular diseases.
Companies in the Plavix market include Bristol-Myers Squibb, Sanofi, Pfizer, AstraZeneca, and Daiichi Sankyo. Show Less Read more